Company Overview - IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry, formed through the merger of IMS Health and Quintiles [11] - The company operates in over 100 countries and employs approximately 88,000 people [11] Investment Ratings - IQVIA is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A [12] - The Growth Style Score for IQVIA is B, indicating a forecasted year-over-year earnings growth of 6.4% for the current fiscal year [12] Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing to $11.84 per share [12] - IQVIA has an average earnings surprise of +1.7%, suggesting a positive trend in earnings performance [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IQVIA is recommended as a potential investment opportunity for growth investors [13]

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute ("TTAM"), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former C ...

Gartner Free Cash Flow May 6, 2025 © 2025 Gartner, Inc. and/or its affiliates. All rights reserved. Gartner is a registered trademark of Gartner, Inc. or its affiliates. This presentation, including all supporting materials, is proprietary to Gartner, Inc. and/or its affiliates and is for the sole internal use of the intended recipients. Because this presentation may contain information that is confidential, proprietary or otherwise legally protected, it may not be further copied, distributed or publicly di ...

Group 1 - Champions Oncology (NASDAQ: CSBR) is a specialized platform providing preclinical research services focused on oncology [1] - The company is at a critical inflection point, evolving its business model by monetizing its unique data asset through licensing [1] Group 2 - The investment thesis suggests that identifying high-quality and/or severely mispriced investment ideas is essential for potential investors [1]

Core Viewpoint - 23andMe has entered into a definitive agreement to sell substantially all of its assets to TTAM Research Institute for $305 million, following a competitive bidding process that included Regeneron Pharmaceuticals as a backup bidder [2][3]. Group 1: Transaction Details - The sale includes the Personal Genome Service (PGS), Research Services business lines, and Lemonaid Health business [2]. - The transaction is subject to approval by the U.S. Bankruptcy Court, with a hearing scheduled for June 17, 2025 [7]. - The agreement with TTAM will replace a previously announced acquisition agreement with Regeneron for $256 million [5]. Group 2: Privacy and Consumer Protections - TTAM has committed to comply with 23andMe's privacy policies and applicable laws, ensuring customer data is processed according to existing consents and privacy statements [4]. - Additional consumer protections include honoring customer rights to delete accounts and genetic data, notifying customers before closing, and establishing a Consumer Privacy Advisory Board within 90 days [6]. - TTAM will offer two years of free identity theft monitoring to customers and will continue to allow de-identified data to be used for research [6].

Invest Heroes LLC is a CIS-based research firm founded in 2018. Since then, we provide equity and fixed income research services which become more and more well-known locally among both professional investors and private clients. Here’s what we do: - Cover top 120+ Russian, US and Chinese stocks - Cover 200+ Russian bonds (corporate, SOE’s) Provide our research as a paid service to several institutional clients, a couple dozen of asset managers/PM’s and about 3000 private clients Our team consists of 2 stra ...

Core Insights - Gartner, Inc. reported first-quarter 2025 results with adjusted earnings per share of $2.98, surpassing the Zacks Consensus Estimate by 9.6% and increasing 1.7% year-over-year. Revenues of $1.5 billion met the consensus estimate and improved 4.2% year-over-year [1] Revenue Segments - Research segment revenues were $1.3 billion, up 4.2% year-over-year on a reported basis and 5.8% on a foreign-currency-neutral basis, with a gross contribution margin of 74.5%, resulting in a gross contribution of $985 million [2] - Consulting segment revenues reached $140 million, growing 3.7% year-over-year on a reported basis and 5.3% on a foreign-currency-neutral basis, with a gross contribution margin of 38.2%, leading to a gross contribution of $53 million [3] - Conferences' revenues totaled $73 million, gaining 3.6% year-over-year on a reported basis and 5.4% on a foreign-currency-neutral basis, with a gross contribution margin of 37.7%, resulting in a gross contribution of $27 million [3] Operating Performance - Adjusted EBITDA for the quarter was $385 million, showing a marginal increase from the year-ago quarter on a reported basis and a 2.9% increase on a foreign-currency-neutral basis [4] Balance Sheet & Cash Flow - At the end of the quarter, Gartner had $2 billion in cash and cash equivalents, up from $1.9 billion in the previous quarter. Long-term debt remained flat at $2.5 billion. Operating cash flow was $313.5 million, with free cash flow utilized at $288 million and capital expenditure totaling $26 million [5] 2025 Outlook - For 2025, Gartner has lowered its total revenue guidance to at least $6.54 billion from the previous estimate of $6.56 billion, which is still above the Zacks Consensus Estimate of $6.51 billion. The adjusted earnings per share guidance was raised to at least $11.70 from $11.45, but remains below the Zacks Consensus Estimate of $12.18 [6] - The adjusted EBITDA guidance has been increased to at least $1.53 billion from $1.51 billion, and free cash flow guidance has been raised to at least $1.15 billion from $1.14 billion [7]

First Quarter 2025 Results May 6, 2025 © 2025 Gartner, Inc. and/or its affiliates. All rights reserved. Gartner is a registered trademark of Gartner, Inc. or its affiliates. This presentation, including all supporting materials, is proprietary to Gartner, Inc. and/or its affiliates and is for the sole internal use of the intended recipients. Because this presentation may contain information that is confidential, proprietary or otherwise legally protected, it may not be further copied, distributed or publicl ...

For the quarter ended March 2025, Universal Display Corp. (OLED) reported revenue of $166.28 million, up 0.6% over the same period last year. EPS came in at $1.35, compared to $1.19 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $154.85 million, representing a surprise of +7.38%. The company delivered an EPS surprise of +26.17%, with the consensus EPS estimate being $1.07.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...